AR038922A1 - 2-HETEROARIL-PYRIMIDINES INHIBITORAS OF CDK, ITS PREPARATION AND ITS USE AS MEDICATIONS - Google Patents
2-HETEROARIL-PYRIMIDINES INHIBITORAS OF CDK, ITS PREPARATION AND ITS USE AS MEDICATIONSInfo
- Publication number
- AR038922A1 AR038922A1 ARP030100819A ARP030100819A AR038922A1 AR 038922 A1 AR038922 A1 AR 038922A1 AR P030100819 A ARP030100819 A AR P030100819A AR P030100819 A ARP030100819 A AR P030100819A AR 038922 A1 AR038922 A1 AR 038922A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- optionally
- hydroxy
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Inhibidores de las quinasas dependientes de las ciclinas, su preparación y su uso como medicamento para el tratamiento de diversas enfermedades. Reivindicación 1: Compuestos de la fórmula general (1), donde: Q es un resto de fórmula (2) ó (3); D, E, G, L, M y T son cada uno, independientemente entre sí, carbono, oxígeno, nitrógeno o azufre, donde al menos debe estar contenido en el anillo un heteroátomo; R1 es hidrógeno, halógeno, alquilo C1-6, alquinilo C1-6, nitro, ciano, heteroarilo o el grupo -COR5, -OCF3, -S-CF3 o -SO2CF3; R2 es hidrógeno, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, heteroarilo o cicloalquilo C3-7 o alquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, heteroarilo o cicloalquilo C3-7, opcionalmente mono polisustituido, igual o diferente, por hidroxi, halógeno, alcoxi C1-6, alquiltio C1-6, amino, ciano, alquilo C1-6, alquenilo C2-6, alcoxi(C1-6)-alquilo(C1-6), alcoxi(C1-6)- alcoxi(C1-6)-alquilo(C1-6), cicloalquilo C3-7, -NHalquilo C1-6, -NHcicloalquilo C3-7, -N(alquilo C1-6)2, -SO(alquilo C1-6), -SO2(alquilo C1-6), alcanoilo C1-6, -CONR3R4, -COR5, alquil(C1-6)OAc, fenilo o por el grupo -R6, el anillo del cicloalquilo C3-7 puede estar opcionalmente interrumpido por uno o varios átomos de nitrógeno, oxígeno y/o azufre y/o puede estar interrumpido en el anillo por uno o varios grupos =C=O y/u opcionalmente pueden estar contenidos en el anillo uno o varios enlaces dobles posibles, y el fenilo, arilo o cicloalquilo C3-7 en sí puede estar opcionalmente mono o polisustituido, igual o diferente, por halógeno, hidroxi, alquilo C1-6, alcoxi C1-6, o por el grupo -CF3 u -OCF3, X es halógeno, oxígeno, azufre o el grupo -NH- o -N(alquilo C1-3)-o X y R2 forman juntos un anillo de cicloalquilo C3-10, que opcionalmente puede contener uno o varios heteroátomos y que opcionalmente puede estar mono o polisustituido por hidroxi, alquilo C1-6, hidroxi-alquilo(C1-6) o halógeno; A y B son cada uno, independientemente entre sí, hidrógeno, hidroxi, halógeno o el grupo -SR7, -S(O)R7, -SO2R7, -NHSO2R7, -CH(OH)R7,-CR7(OH)-R7, alquil(C1-6)P(O)OR3OR4 o -COR7; o Ay B forman juntos un anillo cicloalquilo C3-7 que pueden estar opcionalmente interrumpido por uno o varios átomos de nitrógeno, oxígeno y/o azufre y/o puede estar interrumpido en el anillo por uno o varios grupos =C=O, y/u opcionalmente puede estar contenidos en el anillo uno o varios enlaces dobles posibles y el anillo cicloalquilo C3-7 puede estar opcionalmente mono o polisustituido, igual o diferente, por hidroxi, halógeno, alcoxi C1-6, alquiltio C1-6, amino, ciano, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-7, alcoxi(C1-6)alquilo(C1-6), -NHalquilo C1-6, -N(alquilo C1-6)2, -SO(alquilo C1-6), -SO2(alquilo C1-6), alcanoilo C1-6, -CONR3R4, -COR5, alquil(C1-6)OAc, fenilo, o por el grupo R6, donde el fenilo a su vez puede estar opcionalmente mono o polisustituido, igual o diferente, por halógeno, hidroxi, alquilo C1-6, alcoxi C1-6, o por el grupo -CF3 u -OCF3; R3 y R4 son cada uno, independientemente entre sí, hidrógeno, hidroxi, alcoxi C1-6 o alquilo C1-6 opcionalmente mono o polisustituido, igual o diferente, por hidroxi, alcoxi C1-6, alquiltio C1-6, -N(alquilo C1-6)2, el grupo R6 o -N(alquilo C1-6)R6, R3 y R4 forman juntos un anillo cicloalquilo C3-7 que opcionalmente puede estar interrumpido por uno o varios átomos de nitrógeno, oxígeno y/o azufre y/o puede estar interrumpido en el anillo por uno o varios grupos =C=O, y/u opcionalmente pueden estar contenidos opcionalmente en el anillo uno o varios enlaces dobles posibles; R5 es hidroxi, benzoxi, alquilo C1-6, alquiltio C1-6, o alcoxi C1-6; R6 es un benciltio, feniloxi o anillo cicloalquilo C3-7 opcionalmente mono o polisustituido, igual o diferente, por halógeno, hidroxi, alquilo C1-6, alcoxi(C1-6) o -SO2NR3R4, donde el anillo cicloalquilo C3-7 tiene el significado indicado en R2; R7 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, bencilo, cicloalquilo C3-7, donde el anillo cicloalquilo C3-7 tiene el significado indicado en R2, o el grupo -NR3R4, o alquilo C1-10, alquenilo C2-10, alquinilo C2-10 o cicloalquilo C3-7, opcionalmente mono o polisustituido, igual o diferente, por hidroxi, alcoxi C1-6, halógeno, fenilo, -NR3R4 o fenilo que, a su vez, puede estar opcionalmente mono o polisustituido, igual o diferente, por halógeno, hidroxi, alquilo C1-6, alcoxi C1-6, halo-alquilo C1-6, halo-alcoxi C1-6, o fenilo que, a su vez, puede estar opcionalmente mono o polisustituido, igual o diferente, por halógeno, hidroxi, alquilo C1-6 o alcoxi C1-6, halo-alquilo C1-6, halo-alcoxi C1-6; y n es 0 ó 1, en caso de que n = 0, entonces X es halógeno, así como los isómeros, diastereómeros, enantiómeros y sales de los mismos.Inhibitors of cyclin-dependent kinases, their preparation and their use as a medicine for the treatment of various diseases. Claim 1: Compounds of the general formula (1), wherein: Q is a residue of formula (2) or (3); D, E, G, L, M and T are each, independently of each other, carbon, oxygen, nitrogen or sulfur, where at least one heteroatom must be contained in the ring; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkynyl, nitro, cyano, heteroaryl or the group -COR5, -OCF3, -S-CF3 or -SO2CF3; R2 is hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl or C3-7 cycloalkyl or C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl or C3- cycloalkyl 7, optionally mono-polysubstituted, the same or different, by hydroxy, halogen, C1-6 alkoxy, C1-6 alkylthio, amino, cyano, C1-6 alkyl, C2-6 alkenyl, (C1-6) alkoxy (C1-) alkyl 6), (C1-6) alkoxy - (C1-6) alkoxy-(C1-6) alkyl, C3-7 cycloalkyl, -N C1-6 alkyl, -NH C3-7 cycloalkyl, -N (C1-6 alkyl) 2 , -SO (C1-6 alkyl), -SO2 (C1-6 alkyl), C1-6 alkanoyl, -CONR3R4, -COR5, (C1-6) alkyl OAc, phenyl or by the group -R6, the cycloalkyl ring C3-7 may be optionally interrupted by one or several nitrogen, oxygen and / or sulfur atoms and / or may be interrupted in the ring by one or more groups = C = O and / or optionally may be contained in the ring one or several possible double bonds, and the phenyl, aryl or C3-7 cycloalkyl itself may optionally be mono or polysubstituted, same or different, by halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, or by the group -CF3 or -OCF3, X is halogen, oxygen, sulfur or the group -NH- or -N (C1-3 alkyl ) -o X and R2 together form a C3-10 cycloalkyl ring, which may optionally contain one or more heteroatoms and which may optionally be mono or polysubstituted by hydroxy, C1-6 alkyl, hydroxy (C1-6) alkyl or halogen ; A and B are each, independently of each other, hydrogen, hydroxy, halogen or the group -SR7, -S (O) R7, -SO2R7, -NHSO2R7, -CH (OH) R7, -CR7 (OH) -R7, (C1-6) alkyl P (O) OR3OR4 or -COR7; or Ay B together form a C3-7 cycloalkyl ring that may be optionally interrupted by one or more nitrogen, oxygen and / or sulfur atoms and / or may be interrupted in the ring by one or more groups = C = O, and / or optionally one or several possible double bonds may be contained in the ring and the C3-7 cycloalkyl ring may optionally be mono or polysubstituted, the same or different, by hydroxy, halogen, C1-6 alkoxy, C1-6 alkylthio, amino, cyano , C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, (C1-6) alkoxy (C1-6) alkyl, -N C1-6 alkyl, -N (C1-6 alkyl) 2, -SO (C1 alkyl -6), -SO2 (C1-6 alkyl), C1-6 alkanoyl, -CONR3R4, -COR5, (C1-6) alkyl OAc, phenyl, or by the R6 group, where the phenyl in turn may optionally be mono or polysubstituted, the same or different, by halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, or by the group -CF3 or -OCF3; R3 and R4 are each, independently of each other, hydrogen, hydroxy, C1-6 alkoxy or optionally mono- or polysubstituted C1-6 alkyl, same or different, by hydroxy, C1-6 alkoxy, C1-6 alkylthio, -N (alkyl C1-6) 2, the group R6 or -N (C1-6 alkyl) R6, R3 and R4 together form a C3-7 cycloalkyl ring which may optionally be interrupted by one or more nitrogen, oxygen and / or sulfur atoms and / or it may be interrupted in the ring by one or more groups = C = O, and / or optionally one or several possible double bonds may optionally be contained in the ring; R5 is hydroxy, benzoxy, C1-6 alkyl, C1-6 alkylthio, or C1-6 alkoxy; R 6 is a benzylthio, phenyloxy or C 3-7 cycloalkyl ring optionally mono or polysubstituted, the same or different, by halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy or -SO 2 NR 3 R 4, where the C 3-7 cycloalkyl ring has meaning indicated in R2; R 7 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, benzyl, C 3-7 cycloalkyl, where the C 3-7 cycloalkyl ring has the meaning indicated in R 2, or the group -NR 3 R 4, or C 1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl or C3-7 cycloalkyl, optionally mono or polysubstituted, the same or different, by hydroxy, C1-6 alkoxy, halogen, phenyl, -NR3R4 or phenyl which, in turn, may optionally be mono or polysubstituted, the same or different, by halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, halo- C1-6 alkyl, halo-C1-6 alkoxy, or phenyl which, in turn, may optionally be mono or polysubstituted , same or different, by halogen, hydroxy, C 1-6 alkyl or C 1-6 alkoxy, halo C 1-6 alkyl, halo C 1-6 alkoxy; and n is 0 or 1, in case n = 0, then X is halogen, as well as isomers, diastereomers, enantiomers and salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2002112100 DE10212100A1 (en) | 2002-03-11 | 2002-03-11 | New 2-aminopyrimidine derivatives are cyclin-dependent kinase inhibitors useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases or viral infections |
DE10255984A DE10255984A1 (en) | 2002-11-26 | 2002-11-26 | New 2-aminopyrimidine derivatives are cyclin-dependent kinase inhibitors useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases or viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038922A1 true AR038922A1 (en) | 2005-02-02 |
Family
ID=27806091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100819A AR038922A1 (en) | 2002-03-11 | 2003-03-11 | 2-HETEROARIL-PYRIMIDINES INHIBITORAS OF CDK, ITS PREPARATION AND ITS USE AS MEDICATIONS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1483260A1 (en) |
JP (1) | JP2005526765A (en) |
AR (1) | AR038922A1 (en) |
AU (1) | AU2003212282A1 (en) |
PE (1) | PE20040156A1 (en) |
TW (1) | TW200406406A (en) |
UY (1) | UY27714A1 (en) |
WO (1) | WO2003076437A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
SG176311A1 (en) * | 2002-07-29 | 2011-12-29 | Rigel Pharmaceuticals | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
CN102358738A (en) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-pyrimidinediamine compounds and uses of treating or preventing autoimmune diseases thereof |
DE10349423A1 (en) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments |
JP2008514571A (en) * | 2004-09-29 | 2008-05-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Substituted 2-substituted anilinopyrimidines as cell cycle-kinase or receptor-tyrosine-kinase inhibitors, their preparation and use as pharmaceuticals |
WO2006068770A1 (en) | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
CA2591948C (en) | 2005-01-19 | 2013-11-12 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
EP1710246A1 (en) * | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
ES2651349T3 (en) | 2005-06-08 | 2018-01-25 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibiting the JAK route |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP2009506069A (en) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | Neurogenesis through modulation of muscarinic receptors |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
EP1803723A1 (en) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide derivatives as selective inhibitors of the aurora kinase for the treatment of cancer |
AR059518A1 (en) | 2006-02-17 | 2008-04-09 | Wyeth Corp | METHODS TO PREPARE SUBSTITUTED ALCOHOLS WITH SULFONAMIDS AND THEIR INTERMEDIATE COMPOUNDS |
EP1984347A1 (en) | 2006-02-17 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
JP2009528295A (en) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibition of the JAK pathway |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008092199A1 (en) * | 2007-01-31 | 2008-08-07 | Cytopia Research Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
DE102007010801A1 (en) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi |
PL2252300T3 (en) | 2008-02-22 | 2017-04-28 | Rigel Pharmaceuticals, Inc. | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
JP2011518769A (en) * | 2008-03-14 | 2011-06-30 | ビーエーエスエフ ソシエタス・ヨーロピア | Substituted pyrazinylmethylsulfonamides for use as fungicides |
WO2010025851A1 (en) | 2008-09-03 | 2010-03-11 | Bayer Cropscience Ag | Thienylamino pyrimidines for use as fungicides |
EP2179993A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179991A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179992A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
DE102009001438A1 (en) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome |
DE102009015070A1 (en) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis |
US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
DE102010014426A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
DE102010014427A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluoromethyl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances |
RS56583B1 (en) * | 2010-11-10 | 2018-02-28 | Genentech Inc | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
EA201491732A1 (en) | 2012-03-21 | 2015-08-31 | Байер Интеллектуэль Проперти Гмбх | APPLICATION (RS) -S-CYCLOPROPYL-S- (4 - {[4 - {[(1R, 2R) -2-HYDROXY-1-METHYLPROPIL] OXY} -5- (TRIFTOROMETHYL) Pyrimidine-2-IL] AMINO} PHENYL) SULPHOXIMIDE FOR THE TREATMENT OF SPECIFIC TUMORS |
CA2891412A1 (en) | 2012-11-20 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
US11759450B2 (en) | 2018-02-06 | 2023-09-19 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
CR20200588A (en) * | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Novel compounds |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
WO2020206137A1 (en) | 2019-04-04 | 2020-10-08 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
AR119765A1 (en) | 2019-08-14 | 2022-01-12 | Incyte Corp | IMIDAZOLIL PYRIMIDINILAMINE COMPOUNDS AS CDK2 INHIBITORS |
MX2022004390A (en) | 2019-10-11 | 2022-08-08 | Incyte Corp | Bicyclic amines as cdk2 inhibitors. |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
-
2003
- 2003-02-26 EP EP03708151A patent/EP1483260A1/en not_active Withdrawn
- 2003-02-26 JP JP2003574654A patent/JP2005526765A/en active Pending
- 2003-02-26 WO PCT/EP2003/001995 patent/WO2003076437A1/en active Application Filing
- 2003-02-26 AU AU2003212282A patent/AU2003212282A1/en not_active Abandoned
- 2003-03-10 PE PE2003000240A patent/PE20040156A1/en not_active Application Discontinuation
- 2003-03-11 TW TW092105221A patent/TW200406406A/en unknown
- 2003-03-11 AR ARP030100819A patent/AR038922A1/en unknown
- 2003-03-11 UY UY27714A patent/UY27714A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20040156A1 (en) | 2004-06-07 |
WO2003076437A1 (en) | 2003-09-18 |
UY27714A1 (en) | 2003-10-31 |
JP2005526765A (en) | 2005-09-08 |
AU2003212282A1 (en) | 2003-09-22 |
TW200406406A (en) | 2004-05-01 |
EP1483260A1 (en) | 2004-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR038922A1 (en) | 2-HETEROARIL-PYRIMIDINES INHIBITORAS OF CDK, ITS PREPARATION AND ITS USE AS MEDICATIONS | |
AR046119A1 (en) | PYRIMIDINES REPLACED WITH SULFOXIMINE AS CDK AND / OR VEGF INHIBITORS ITS PREPARATION AND ITS USES AS A MEDICINAL PRODUCT | |
AR036586A1 (en) | NEW DIHYDRO-PTERIDINONES, PROCEDURES FOR THEIR PREPARATION, ITS USE AS MEDICATIONS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | |
PE20130149A1 (en) | DERIVATIVES OF CHROMENONE WITH ANTI-TUMOR ACTIVITY | |
AR069510A1 (en) | ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10 | |
ECSP105253A (en) | DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS INHIBITORS OF PI3 CINASA | |
AR073138A1 (en) | DIOXA-BICYCLE DERIVATIVES (3.2.1) OCTANO- 2,3,4-TRIOL | |
AR077468A1 (en) | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS | |
PE20141404A1 (en) | DERIVATIVES OF HAVE [3,2-D] PYRIMIDINE WHICH HAVE INHIBITING ACTIVITY BY KINASES OF PROTEINS | |
AR045761A1 (en) | DERIVATIVES OF 2-PIRIDONA AS INHIBITORS OF ELASTASA DE NEUTROFILOS | |
PE20151776A1 (en) | HETEROARYL COMPOUNDS AND THEIR USES | |
PE20080263A1 (en) | PIRROLO-PYRIMIDINE COMPOUNDS AND THEIR USES | |
ES2328820T3 (en) | DERIVATIVES OF 4- (PIRAZOL-3-ILAMINO) PYRIMIDINE FOR USE IN CANCER TREATMENT. | |
PE20071420A1 (en) | SUBSTITUTE PYRROLOPYRIDINES, COMPOSITIONS CONTAINING THEM AND MANUFACTURING PROCESS | |
AR056511A1 (en) | DERIVATIVES OF 2-AMINOPIRIMIDINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HISTAMINE RECEIVER H4 | |
AR063099A1 (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN QUINASA | |
NO20064365L (en) | Therapeutic compound | |
AR076460A1 (en) | CXCR3 RECEIVER ANTAGONISTS | |
PE20060777A1 (en) | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | |
AR042024A1 (en) | PHARMACEUTICAL COMPOUNDS DERIVED FROM PIRIDONA, PIRIMIDONA AND PIRAZINONA | |
ECSP066947A (en) | PHARMACOLOGICAL COMBINATIONS CONTAINING BENZOXAZINE FOR THE TREATMENT OF RESPIRATORY ROAD DISEASES | |
AR063925A1 (en) | ANTIBACTERIALS 5-HYDROXIMETHYL -OXAZOLIDIN-2-ONA PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE TO TREAT OR PREVENT BACTERIAL INFECTIONS | |
AR055744A1 (en) | DERIVATIVES OF PYRIMIDINCARBOXILIC ACID, ITS USE TO PREPARE MEDICINES AND PREPARATION OF COMPOUND DICJHOS | |
AR070345A1 (en) | (DIHIDRO) PIRROLO (2,1-A) ISOQUINOLINAS | |
AR057625A1 (en) | PIRIMIDINONE OR PIRIMIDINATIONA COMPOUNDS, OBTAINING PROCESSES, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |